These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. Whitcup SM; Fortin E; Lindblad AS; Griffiths P; Metcalf JA; Robinson MR; Manischewitz J; Baird B; Perry C; Kidd IM; Vrabec T; Davey RT; Falloon J; Walker RE; Kovacs JA; Lane HC; Nussenblatt RB; Smith J; Masur H; Polis MA JAMA; 1999 Nov; 282(17):1633-7. PubMed ID: 10553789 [TBL] [Abstract][Full Text] [Related]
6. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. Macdonald JC; Torriani FJ; Morse LS; Karavellas MP; Reed JB; Freeman WR J Infect Dis; 1998 May; 177(5):1182-7. PubMed ID: 9593001 [TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis. Walmsley SL; Raboud J; Angel JB; Mazzulli T; Shen S; Casciaro L; Young CD; Moussa G; Gough K; Rachlis A; Hopkins J HIV Clin Trials; 2006; 7(1):1-9. PubMed ID: 16632459 [TBL] [Abstract][Full Text] [Related]
8. Highly active antiretroviral therapy-associated regression of cytomegalovirus retinitis: long-Term results in a small case series. Reed JB; Briggs JW; McDonald JC; Freeman WR; Morse LS Retina; 2001; 21(4):339-43. PubMed ID: 11508879 [TBL] [Abstract][Full Text] [Related]
10. Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis. Macdonald JC; Karavellas MP; Torriani FJ; Morse LS; Smith IL; Reed JB; Freeman WR Ophthalmology; 2000 May; 107(5):877-81; discussion 881-3. PubMed ID: 10811078 [TBL] [Abstract][Full Text] [Related]
11. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. Tural C; Romeu J; Sirera G; Andreu D; Conejero M; Ruiz S; Jou A; Bonjoch A; Ruiz L; Arnó A; Clotet B J Infect Dis; 1998 Apr; 177(4):1080-3. PubMed ID: 9534987 [TBL] [Abstract][Full Text] [Related]
12. High-dose (5000-microg) intravitreal ganciclovir combined with highly active antiretroviral therapy for cytomegalovirus retinitis in HIV-infected patients in Venezuela. Arevalo JF; Garcia RA; Mendoza AJ Eur J Ophthalmol; 2005; 15(5):610-8. PubMed ID: 16167292 [TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy in HIV infected patients: natural history and clinical predictors. Lin DY; Warren JF; Lazzeroni LC; Wolitz RA; Mansour SE Retina; 2002 Jun; 22(3):268-77. PubMed ID: 12055458 [TBL] [Abstract][Full Text] [Related]
14. Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease. Verbraak FD; Boom R; Wertheim-van Dillen PM; van den Horn GJ; Kijlstra A; de Smet MD Br J Ophthalmol; 1999 Oct; 83(10):1186-9. PubMed ID: 10502584 [TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Whitcup SM JAMA; 2000 Feb; 283(5):653-7. PubMed ID: 10665706 [TBL] [Abstract][Full Text] [Related]
16. Characteristics of untreated AIDS-related cytomegalovirus retinitis. II. Findings in the era of highly active antiretroviral therapy (1997 to 2000). Holland GN; Vaudaux JD; Shiramizu KM; Yu F; Goldenberg DT; Gupta A; Carlson M; Read RW; Novack RD; Kuppermann BD; Am J Ophthalmol; 2008 Jan; 145(1):12-22. PubMed ID: 18154751 [TBL] [Abstract][Full Text] [Related]
17. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Vrabec TR; Baldassano VF; Whitcup SM Ophthalmology; 1998 Jul; 105(7):1259-64. PubMed ID: 9663231 [TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years. Labetoulle M; Goujard C; Frau E; Rogier H; Niessen F; Furlan V; Lantz O; Lecointe D; Delfraissy JF; Offret H J Acquir Immune Defic Syndr; 1999 Nov; 22(3):228-34. PubMed ID: 10770342 [TBL] [Abstract][Full Text] [Related]
19. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. Deayton J; Mocroft A; Wilson P; Emery VC; Johnson MA; Griffiths PD AIDS; 1999 Jul; 13(10):1203-6. PubMed ID: 10416523 [TBL] [Abstract][Full Text] [Related]
20. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. Wohl DA; Kendall MA; Owens S; Holland G; Nokta M; Spector SA; Schrier R; Fiscus S; Davis M; Jacobson MA; Currier JS; Squires K; Alston-Smith B; Andersen J; Freeman WR; Higgins M; Torriani FJ; HIV Clin Trials; 2005; 6(3):136-46. PubMed ID: 16192248 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]